1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Precipio, Inc.
  6. Summary
    PRPO   US74019L5030

PRECIPIO, INC.

(PRPO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
1.07(c) 1.08(c) 1.11(c) 1.12(c) 1.16(c) Last
104 750 843 897 98 631 63 269 64 301 Volume
0.00% +0.93% +2.78% +0.90% +3.57% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 20,9 M - -
Net income 2022 -4,82 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,52x
Yield 2022 -
Sales 2023 37,0 M - -
Net income 2023 0,12 M - -
Net Debt 2023 - - -
P/E ratio 2023 116x
Yield 2023 -
Capitalization 26,3 M 26,3 M -
Capi. / Sales 2022 1,26x
Capi. / Sales 2023 0,71x
Nbr of Employees 56
Free-Float 96,8%
More Financials
Company
Precipio, Inc. is a healthcare solutions company that is focused on cancer diagnostics. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells,... 
More about the company
Ratings of Precipio, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about PRECIPIO, INC.
05/24Precipio Shares Rise on Regulatory Approval for Sale of Screening Technology in Europea..
MT
05/24Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
AQ
05/11PRECIPIO, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/11Precipio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Precipio Signs First IV-Cell Customer Agreement
AQ
05/10Precipio Signs First IV-Cell Customer Agreement
CI
04/26Precipio customer American Oncology Network (AON) selected to present HemeScreen® techn..
AQ
04/04TRANSCRIPT : Precipio, Inc., Q4 2021 Earnings Call, Apr 04, 2022
CI
03/30PRECIPIO, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
03/30Precipio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/23PRECIPIO : Announces 2021 Fourth Quarter and Year-End Shareholder Update Call - Form 8-K
PU
03/23PRECIPIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
03/22Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call
AQ
03/21PRECIPIO : Announces the Resignation of its Chief Financial Officer and Appointment of Int..
PU
03/21PRECIPIO, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Fina..
AQ
More news
News in other languages on PRECIPIO, INC.
05/24Les actions Precipio augmentent suite à l'approbation réglementaire de la vente de la t..
05/11Precipio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/10Precipio signe le premier accord avec un client de IV-Cell
03/30Precipio, Inc. annonce ses résultats pour l'année complète se terminant le 31 décembre ..
03/21Le directeur financier de Precipio démissionne ; Matt Gage est nommé directeur financie..
More news
Analyst Recommendations on PRECIPIO, INC.
More recommendations
Chart PRECIPIO, INC.
Duration : Period :
Precipio, Inc. Technical Analysis Chart | PRPO | US74019L5030 | MarketScreener
Technical analysis trends PRECIPIO, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,16 $
Average target price 4,00 $
Spread / Average Target 245%
EPS Revisions
Managers and Directors
Ilan Danieli Chief Executive Officer & Director
Matthew Gage CFO, Director-Financial Report & Analysis
Richard Alvin Sandberg Chairman
Ayman A. Mohamed Vice President-Research & Development
Ahmed Zaki Sabet Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
PRECIPIO, INC.-26.58%26
SARTORIUS AG-31.06%25 907
REVENIO GROUP OYJ-13.27%1 371
BIOTAGE AB (PUBL)-23.66%1 341
VAREX IMAGING CORPORATION-27.42%912
CELLAVISION AB (PUBL)6.24%838